CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Status:
Withdrawn
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II clinical trial to test safety and efficacy of combining CD24Fc with
ipilimumab and nivolumab to decrease irAE, with built-in interim analyses, and safety and
response stopping rules.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
OncoImmune, Inc.
Collaborators:
Huntsman Cancer Institute National Cancer Institute (NCI)